US Spent $1.49B On Cannabis Research from 2000-2018

The United States spent $1.49 billion on cannabis research between 2000 and 2018. Most of the funds were directed at understanding the potential harms of cannabis use.

The United States spent $1.49 billion on cannabis funding from 2000-2018, according to a Science report. The majority of the funds were spent on understanding potential harms from cannabis use.

Top Marijuana Stock To Expand In Canada's Biggest Retail Market

Canopy Growth (CGC) on Friday said it would open 10 physical retail locations next week in Alberta, the first of its stores to appear in a province that already has far more pot shops than any other. Canopy Growth stock and other marijuana stocks rose.

The company, which is the biggest marijuana stock by market cap, said it would open both its Tweed and Tokyo Smoke shops in the province, with most appearing in Calgary. Canopy said it was hiring 100 people in Alberta connection with the openings.

Cannabis research database shows how U.S. funding focuses on harms of the drug

A new analysis of cannabis research funding in the United States, Canada, and the United Kingdom has found that $1.56 billion was directed to the topic between 2000 and 2018—with about half of the money spent on understanding the potential harms of the recreational drug. Just over $1 billion came from the biggest funder, the U.S. National Institute on Drug Abuse (NIDA), which doled out far more money to research cannabis misuse and its negative effects than on using cannabis and cannabis-derived chemicals as a therapeutic drug.

When Will Aurora Cannabis Snap Out Of This Perpetual Trend To The Downside?

Although Aurora Cannabis (ACB.TO) (ACB) does not have the best track record with maintaining business relationships, the new management team has help keep things under control…until now.

Yesterday, CTT Pharmaceutical Holdings, Inc., (CTTH), an innovative life sciences company with a portfolio of intellectual property (IP) in novel drug delivery systems, reported to have filed a statement of claim with the Ontario Superior Court of Justice against Aurora Cannabis.

A US-Focused Cannabis ETF Is Finally On The Way

Through boom and burst of the cannabis equity cycle, two things became abundantly clear: multi-state operators (MSOs) often outperformed their Canadian rivals and accessing MSOs through most New York-listed marijuana exchange-traded funds was difficult.

What Happened: Accessing cannabis MSOs via the ETF wrapper will soon get easier because AdvisorShares is launching the AdvisorShares Pure US Cannabis ETF NYSEMSOS on Sept. 2.

Colorado: Debate Continues Ahead of Rulemaking on Cannabis and Equity

Stakeholders, focused on forthcoming recommendations for how a social equity bill should be implemented, debated the details that define equity, from income to disproportionately impacted areas.

Last week’s Colorado Department of Revenue Marijuana Enforcement Division rulemaking workgroup on how a social equity bill will be implemented zeroed in on local control, income thresholds for applicants, and the definition of disproportionately impacted areas. 

Cannabis-Infused Beverages Will Be Big Business In 2021

Three reasons why liquid weed is poised to skyrocket.

Look for cannabis-infused drinks to make a splash next year. According to the ‘Disrupting Drinks’ report published by cannabis market intelligence firm Prohibition Partners, cannabis drinks are likely to pose a threat to the dominating alcoholic beverage industry. The report also states that the market for cannabis-infused drinks is expected to rise to an estimated $4 billion by 2024. 

Pennsylvania Banks On Marijuana Legalization To Help Pandemic Budget Crisis. Here’s Why It Won’t Work (And Why That’s A Problem).

Pennsylvania is deep in the red, and the culprit is COVID-19. But if the federal government can’t save the state, can marijuana?

That’s what the Keystone State appears poised to try. If it does, the state might need to prepare to be disappointed.

Gov. Tom Wolf imposed strict social-distancing measures in March to smash the novel coronavirus, and while it worked—Pennsylvania’s rate of new infections is among the lowest in the United States—it came at great cost.